The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 3 study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma.
Nathan Hale Fowler
Consultant or Advisory Role - Celgene; Gilead Sciences; Pharmacyclics; Roche
Research Funding - Celgene; Gilead Sciences; Janssen; Roche
Wolfgang Hiddemann
No relevant relationships to disclose
John Leonard
Consultant or Advisory Role - Pharmacyclics (U)
Esther Rose
Consultant or Advisory Role - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Tahamtan Ahmadi
Employment or Leadership Position - Janssen Research & Development
Jessica Vermeulen
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Janssen
Julie S. Larsen
Employment or Leadership Position - Janssen Pharmaceutical
Stock Ownership - Janssen Pharmaceutical
Steven Sun
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Lisa Mentzer
No relevant relationships to disclose
Shean-Sheng Wang
Employment or Leadership Position - Janssen Pharmaceutical
Stock Ownership - Johnson & Johnson
Tzu-Min Yeh
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Gilles A. Salles
Consultant or Advisory Role - Janssen
Research Funding - Janssen